These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 22222285)

  • 1. List of drugs in development for neurodegenerative diseases: update October 2011.
    Pogačić Kramp V
    Neurodegener Dis; 2012; 9(4):210-83. PubMed ID: 22222285
    [No Abstract]   [Full Text] [Related]  

  • 2. List of drugs in development for neurodegenerative diseases: update June 2009.
    Pogacić Kramp V; Herrling P
    Neurodegener Dis; 2009; 6(4):165-212. PubMed ID: 19696517
    [No Abstract]   [Full Text] [Related]  

  • 3. List of drugs in development for neurodegenerative diseases: update June 2010.
    Pogačić Kramp V; Herrling P
    Neurodegener Dis; 2011; 8(1-2):44-94. PubMed ID: 20689264
    [No Abstract]   [Full Text] [Related]  

  • 4. List of drugs in development for neurodegenerative diseases. Update June 2007.
    Pogacić V; Herrling P
    Neurodegener Dis; 2007; 4(6):443-86. PubMed ID: 17934328
    [No Abstract]   [Full Text] [Related]  

  • 5. List of drugs in development for neurodegenerative diseases. Update June 2006.
    Kwon MO; Herrling P
    Neurodegener Dis; 2006; 3(3):148-86. PubMed ID: 16954701
    [No Abstract]   [Full Text] [Related]  

  • 6. List of drugs in development for neurodegenerative diseases. Update September 2005.
    Kwon MO; Herrling P
    Neurodegener Dis; 2005; 2(2):61-108. PubMed ID: 16909049
    [No Abstract]   [Full Text] [Related]  

  • 7. List of drugs in development for neurodegenerative diseases. Update March 2005.
    Valentine L; Kwon MO; Herrling P
    Neurodegener Dis; 2004; 1(6):269-322. PubMed ID: 16908978
    [No Abstract]   [Full Text] [Related]  

  • 8. List of drugs in development for neurodegenerative diseases. Update June 2004.
    Kwon MO; Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(2-3):113-52. PubMed ID: 16908983
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenges and opportunities in neuroscience research.
    Coleman PJ; Barrow JC
    ChemMedChem; 2012 Mar; 7(3):339-41. PubMed ID: 22383223
    [No Abstract]   [Full Text] [Related]  

  • 10. List of drugs in development for neurodegenerative diseases. Update June 2008.
    Pogacić V; Herrling P
    Neurodegener Dis; 2009; 6(1-2):37-86. PubMed ID: 18679022
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug discovery for neurodegenerative diseases: challenges and novel biochemical targets dedicated to the memory of Mark A. Smith for his inspiring contribution to Alzheimer's disease.
    Britton GB; Smith MA; Perry G; Sambamurti K; Jagannatha Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():1-2. PubMed ID: 21525570
    [No Abstract]   [Full Text] [Related]  

  • 12. List of drugs in development for neurodegenerative diseases.
    Fischer F; Matthisson M; Herrling P
    Neurodegener Dis; 2004; 1(1):50-70. PubMed ID: 16908974
    [No Abstract]   [Full Text] [Related]  

  • 13. Foreword: neurodegenerative diseases: challenges and opportunities.
    Cuny GD
    Future Med Chem; 2012 Sep; 4(13):1647-9. PubMed ID: 22924500
    [No Abstract]   [Full Text] [Related]  

  • 14. Translational Research and Drug Discovery for Neurodegeneration: Challenges for Latin America.
    Rao KSJ; Britton GB; Rocha Arrieta LL; Garcia-Cairasco N; Lazarowski A; Palacios A; Camins Espuny A; Maccioni RB
    J Alzheimers Dis; 2021; 82(s1):S1-S4. PubMed ID: 34092644
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: Neurodegeneration, Oxidative Stress, Metabolic Syndrome, Drug Design and Development: Clinical Implications.
    Cacabelos R; Reddy VP; Aliev G
    CNS Neurol Disord Drug Targets; 2016; 15(2):126. PubMed ID: 26907796
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

  • 17. Preface Drug discovery in neurodegenerative disorders: a defeat for pharmacology?
    Caraci F; Kraneveld A; Krzan M; Luca MD
    Eur J Pharmacol; 2017 Dec; 817():1. PubMed ID: 29162230
    [No Abstract]   [Full Text] [Related]  

  • 18. The emergence of designed multiple ligands for neurodegenerative disorders.
    Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
    Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonprofit foundations spur translational research.
    Zaratin P; Battaglia MA; Abbracchio MP
    Trends Pharmacol Sci; 2014 Nov; 35(11):552-5. PubMed ID: 25441773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic applications of iminosugars: current perspectives and future opportunities.
    Horne G; Wilson FX
    Prog Med Chem; 2011; 50():135-76. PubMed ID: 21315930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.